This clinical trial is focused on studying the effects of a new treatment called IMG-007 for adults with atopic dermatitis, a condition also known as eczema, which causes the skin to become red, inflamed, and itchy. The study aims to evaluate the safety and effectiveness of IMG-007 in individuals with moderate to severe forms of this skin condition. Participants in the study will receive IMG-007 through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. Some participants may receive a placebo, which looks like the treatment but does not contain the active ingredient.

The purpose of the study is to assess any side effects that may occur with the use of IMG-007 and to understand how the body processes the medication. The study will also measure changes in the severity of the skin condition over a period of 12 weeks. Participants will be monitored closely by healthcare professionals throughout the study to ensure their safety and to gather important information about the treatment’s impact on their condition.

During the study, participants will be required to apply a non-medicated moisturizer regularly to help manage their skin condition. The study will involve regular visits to the clinic for assessments and to receive the treatment. This research is an important step in finding new and effective treatments for people living with atopic dermatitis.